世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

乾癬性関節炎治療薬の市場予測 - 疫学とパイプラインの分析 2022-2027


Psoriatic Arthritis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027

乾癬性関節炎治療薬の世界市場は、2022年から2027年にかけて年平均成長率8.09％で成長すると予測されています。 市場インサイト 乾癬性関節炎（PsA）は、痛み、こわばり、関節の腫れ、関節びらん、骨形成を... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Arizton Advisory & Intelligence
アリズトンアドバイザリー&インテリジェンス 		2022年10月20日 US$3,750
シングルユーザライセンス（印刷不可）
ライセンス・価格情報・注文方法はこちら 		270 英語

　

サマリー

乾癬性関節炎治療薬の世界市場は、2022年から2027年にかけて年平均成長率8.09％で成長すると予測されています。

市場インサイト

乾癬性関節炎（PsA）は、痛み、こわばり、関節の腫れ、関節びらん、骨形成を特徴とする異質な慢性炎症性リウマチ性疾患です。乾癬性関節炎は、乾癬患者の最大30％に発症し、最も多いのは30歳から60歳の患者です。多くの人は乾癬が発症してから約10年後に発症しますが、中には乾癬を発症することなく、あるいは乾癬に気づくことなく、先にPsAを発症する人もいます。PsAは年齢に関係なく発症し、男性でも女性でも同じように発症します。近年では、女性の方が関節症性乾癬の発症リスクが高いことから、世界の関節症性乾癬治療薬市場への貢献度が高くなっています。なお、欧州では200万人以上、米国では約50万人が関節症に罹患していると推定されています。

PsAの正確な原因はまだわかっていません。家族歴が強く関与しており、発症者の約40%は家族に乾癬や関節炎の患者がいると言われています。危険因子としては、肥満、重症の乾癬、爪の病気、外傷や外傷部位の深部病変などが考えられます。

- 乾癬性関節炎の診断。

乾癬性関節炎を診断するための特別な検査はありません。症状は、関節リウマチ、反応性関節炎、痛風などの他の関節炎疾患と似ています。診断には、X線、CTスキャン、超音波、MRI、皮膚生検などの画像診断が行われます。

- 乾癬性関節炎治療。

治療は、痛み、腫れ、こわばりの程度によって異なります。ごく軽度の関節炎であれば、関節に痛みがあるときだけ治療が必要で、良くなったら治療を中止することもできます。乾癬性関節炎の主な治療法は、初期治療としてイブプロフェン（モトリンやアドビル）やナプロキセン（アリーブ）などの非ステロイド性抗炎症薬を使用します。関節炎が反応しない場合は、疾患修飾性抗リウマチ薬が処方されます。スルファサラジン（アズルフィジン）、メトトレキサート（リウマトレックス、トレキソール、オトレキザップ、ラスボ）、シクロスポリン（ネオーラル、サンディミュン、ゲングラフ）、レフルノミドなどがこれにあたります。これらの薬剤を組み合わせて使用することもあります。アザチオプリン（イムラン）は重症のPSA患者さんに効果があります。

その他の治療法としては、adalimumab（ヒュミラ）、certolizumab pegol（シムジア）、etanercept（エンブレル）、golimumab（シンポニ）、infliximab（Remicade）といったTNF阻害剤から始まる生物学的製剤が一般的に使用されます。PsAに使用されるその他の生物学的製剤には、IL-17A阻害剤のセクキヌマブ（コセンティクス）、イキセキズマブ（タルツ）、IL-12/23阻害剤のウステキヌマブ（ステラーラ）、IL-23阻害剤のリサンキズマブ-rzaa（スカイリジ）、グゼルクマブ（トレムフィア）などや、他のクラスのアバタセプト（オレンシア）などが含まれます。また、トファシチニブ（ゼルヤンツ）、ウパダシチニブ（リンボック）、アプレミラスト（オテズラ）などの新しい内服薬も有効であることが示されています。

主な特長

関節症性乾癬治療薬市場のポートフォリオには、様々な開発段階にある合計25以上の資産が含まれています。乾癬性関節炎のために活発に臨床開発が行われている業界提供の薬剤のほとんどは、第III相の段階にあります。乾癬性関節炎の新興治療薬には、Bimekizumab、Tildrakizumab、SHR-0302、Neihulizumab、およびその他多くのものが含まれます。これらの新規の新興医薬品を発売することで、近い将来、PsA治療のパラダイムが変化することでしょう。25以上の分子が様々な開発段階にあり、既存の特許取得済みの関節症性乾癬治療薬と比較して、新規作用機序と優れた安全性および有効性プロファイルを有する新規ベンダーが業界に参入する可能性が高いと予想されます。

- 乾癬性関節炎臨床試験シナリオ

臨床試験ポートフォリオには、様々な開発フェーズにある150以上の試験が含まれています。業界がスポンサーとなっているPSAのための活発な臨床開発中の薬剤のほとんどは、第III相の段階にある。第Ⅰ相から第Ⅳ相にわたる臨床試験の分布は、乾癬性関節炎のための試験の大部分が開発の後期段階にあることを示しており、試験の58％が第Ⅱ/Ⅲ＆Ⅲ相にあり、第Ⅰ-Ⅱ相は41％のみである。

マーケットドライバー＆トレンド

- 生物学的製剤の採用が進む

関節症性乾癬治療薬市場では、抗腫瘍壊死因子（TNF）抗体や抗インターロイキン抗体などの生物学的製剤が広く使用されています。2013年にステララが乾癬性関節炎の生物学的製剤として承認されたことにより、現在提供されている薬剤よりも免疫原性が低く、新しい作用機序を持つ治療薬に対する需要が高まっています。今後数年間で、多くの新しいクラスの治療薬が関節症性乾癬治療市場に参入することが予想されます。インターロイキン阻害剤などの生物学的製剤は、より優れた臨床プロファイルと患者の利便性を考慮し、関節症性乾癬の市場に進出しています。

- 期待される新薬の上市

乾癬性関節炎治療のために処方される生物学的製剤の最近の波は、おそらく有利な機会を生み出すと思われます。現在、関節症性乾癬の患者さんには多くの治療法が提供されていますが、関節症性乾癬の治療市場にはまだ改善の余地があります。
アリズトンでは、8MMのうち、インターロイキン（IL）阻害剤2剤（Bimekizumab、Tildrakizumab）、経口ヤヌスキナーゼ（JAK）阻害剤2剤（Filgotinib、SHR0302）、経口チロシンキナーゼ2（TYK2）阻害剤1剤（Deucravacitinib）を含む5剤の上市を予定しています。これらの後期開発薬の上市は、世界の関節症性乾癬治療薬市場の成長機会を創出するものです。

- 新規メカニズムによる新薬に注目

過去7年間、腫瘍壊死因子（TNF）以外の炎症経路を遮断する薬剤が、関節症性乾癬（PsA）治療の新たな選択肢となっています。IL-23/IL-17軸を標的とした治療薬は、関節症性乾癬に非常に有効であることが証明されており、既に治療薬として使用されているものもあれば、開発中のものもある。IL-23/IL-17軸のサイトカインは、乾癬やPsAの病態形成に必須の因子である。モノクローナル抗体によるIL-23およびIL-17の阻害は、関節症性乾癬の治療市場において非常に有効な治療法です。アリズトンでは、今後5年間で、研究開発パイプラインから生まれるイノベーションの急増と、介入に対するエビデンスベースを拡大し、アウトカムに測定可能な改善をもたらす、テクノロジーを活用した様々な変革が起こると予想しています。

セグメンテーション分析

- 薬剤クラスTNF-α阻害剤は、世界の関節症性乾癬治療薬市場で大きなシェアを占めています。しかし、予測期間中はインターロイキン阻害剤が最も急成長するセグメントとなることが予想されます。最近承認されたスカイリジ（risankizumab-rzaa）やコセンティクス（Secukinumab）などのインターロイキン阻害剤は、予測期間中に世界の乾癬性関節炎治療薬市場を牽引すると予想されます。

薬物クラスによる区分
- TNF阻害剤
- インターロイキン阻害剤
- 非ステロイド性抗炎症薬
- その他の薬物クラス

- 性別タイプ性別による区分では、女性が世界の関節症性乾癬治療薬市場で大きなシェアを占めています。これは、近年、女性が関節症性乾癬のリスクをより高めているためです。

性別タイプ別セグメント
- 男性
- 女性

- 疾患の種類蹄鉄炎が大きなシェアを占めると予想されます。しかし、予測期間中は、乳頭炎が最も急速に成長すると予想されます。

疾患タイプ別セグメント
- 脊椎炎
- 咬合炎
- 乳突出部炎

- 年齢層年齢層：50歳以下が関節症性乾癬治療剤の世界市場で大きなシェアを占めると予想されます。

年齢層別セグメント
- 50歳以下
- 50歳以上

- 重症度タイプ重症度別では、軽症者が世界の関節症性乾癬治療薬市場で大きなシェアを占めると予想されます。しかし、予測期間中は、中等症の人々が最も急速に成長するセグメントとなることが予想されます。

重症度別セグメント
- 中等症
- 軽度
- 重度

地域別展望

米国は、医療費負担の軽さ、国民の知識・意識の高さ、技術の進歩により、世界の乾癬性関節炎治療薬市場を地域別に支配しています。しかし、ドイツは、医療へのアクセスと質の向上、疾病管理に関する意識の高まり、この地域における医療費の増加により、PsA治療薬産業において高いCAGRで成長すると予想されます。中国や日本などの新興市場におけるバイオシミラーの動向は、この地域の乾癬性関節炎の治療状況を変化させる可能性があります。

アリズトンの推定によると、2020年の乾癬性関節炎の有病率は中国が高く、次いでスペイン、イギリスとなっています。乾癬性関節炎の有病率の増加は、乾癬性関節炎治療市場の成長を後押ししています。推定によると、欧州連合では2014年に200万人以上がPsAに罹患しています。

地域別セグメント

- 北アメリカ
o 米国
- APAC
o 中国
o 日本
- 欧州
o 英国
o フランス
o ドイツ
o イタリア
スペイン

競争環境

世界の乾癬性関節炎治療市場は、ジェネリック医薬品を提供する多くの企業と、PsA治療のための特許・商用薬を提供する選択的な製薬/バイオテクノロジー企業によって支配されています。米国食品医薬品局（FDA）は、2013年にインターロイキン抗体であるステラーラ（ウステキヌマブ）を乾癬性関節炎の治療薬として承認しています。最近では、2022年にSkyrizi（risankizumab-rzaa）、2021年にCosentyx（secukinumab）などのインターロイキンがPsA治療薬としてFDAに承認されています。ジェネリック医薬品は引き続き乾癬性関節炎治療薬の市場シェアを大きく獲得していますが、生物学的製剤やその他の標的治療薬の登場は、予測期間を通じてこの治療領域のパラダイムシフトを示唆しています。

アッヴィー、ジョンソン・エンド・ジョンソン、武田薬品工業、バイオジェン、UCB SA、アムジェン、ブリストル・マイヤーズスクイブ、ファイザー、イーライ・リリー・アンド・カンパニー、ノバルティスといった企業が、世界の乾癬性関節炎治療市場における主要プレイヤーとして名を連ねています。これらのプレイヤーは、製品ポートフォリオを強化するために成長戦略の採用に注力しています。これらの企業は、世界の乾癬性関節炎治療市場で競争するために、共同研究＆買収、地理的フットプリントの拡大、研究開発への投資、新規薬剤の製造などの戦略を採用しています。

関節症性乾癬治療市場で活動するその他の著名なプレーヤーには、Sun Pharmaceuticals社、Bausch Health Companies Inc社、Jiangsu HengRui Medicine Co.Ltd.、Biocad Biopharmaceutical、Meiji Holdings Co Ltd.、Bio-Theraなどがあります。これらの企業は、技術的に高度で革新的な乾癬治療薬を開発するための研究開発イニシアチブに注力しており、業界内での地位を維持するために共同研究にも着手しています。

主要ベンダ
- アッヴィ（AbbVie）社
- ジョンソン・エンド・ジョンソン
- UCB SA
- アムジェン
- ブリストル・マイヤーズ スクイブ
- ファイザー
- イーライリリー・アンド・カンパニー
- ノバルティス

その他の有力ベンダー
- サムスンバイオエピス
- ベーリンガーインゲルハイム
- マイラン
- メルク・アンド・カンパニー・インク
- コヘルスバイオサイエンス

後期パイプライン医薬品を有する主要新興ベンダー
- サン・ファーマシューティカルズ
- バウシュヘルスカンパニーズ
- 江蘇恒瑞医薬有限公司江蘇恒瑞医薬有限公司
- バイオキャド・バイオファーマシューティカル
- 明治ホールディングス
- バイオセラ

レポート対象製品

- 関節症性乾癬治療市場の詳細な概要（疾患の定義、分類、診断、治療パターンなど）。
- 主要8市場（8MM）における関節症性乾癬治療市場の世界動向の概要
- 2018年～2027年の主要8市場（8MM）におけるPsAの過去、現在、予測患者数
- 製品、治療法、競合他社分析を含む市場セグメントの詳細分析
- 乾癬性関節炎治療の市場プレイヤーの市場シェア、企業プロファイル、製品仕様、競合環境など
- 新興トレンド、市場促進要因、成長機会、阻害要因に関する包括的なデータ
- スポンサー名、承認された適応症、領域、共同研究、ライセンス、M&A、規制指定、その他の製品関連活動など、開発活動を主要にカバーした上市薬の詳細な概要。
- 治療用パイプライン活動の詳細な概要と、臨床および非臨床の全段階を含む製品開発サイクル全体にわたるPSAの開発段階、製品タイプ、投与経路、分子タイプ、MOAタイプによる製品の治療評価
- 乾癬性関節炎に関する臨床試験活動の詳細な概要と、すべての臨床ステージにおける開発ステージ、製品タイプ、投与経路、分子タイプ、地理的タイプごとの製品の治療評価
- PsAにおける休眠および中止されたパイプラインプロジェクトをその理由とともに掲載
- 乾癬性関節炎治療市場における重要なマイルストーン（製品承認/上市のスケジュール、臨床試験結果の公表、規制当局の指定、ライセンスおよび共同研究、パイプライン資産の研究開発進捗）のカバレッジ。

回答された主な質問
1.乾癬性関節炎治療薬の世界市場規模はどのくらいか？
2.関節症性乾癬治療薬の世界市場の成長率は？
3.関節症性乾癬治療薬市場の成長を促進する要因は何か？
4.関節症性乾癬治療市場で事業を展開している主要ベンダはどこか？
5.世界の関節症性乾癬治療市場で最大のシェアを占める地域はどこか？


ページTOPに戻る


目次

1. PSORIATIC ARTHRITIS OVERVIEW
1.1. Psoriatic Arthritis Disease – An Overview

2. PSORIATIC ARTHRITIS EPIDEMIOLOGY & OVERVIEW
2.1. 8MM: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.2. 8MM: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.3. 8MM: Historic & Projected Volume of incidence of Psoriatic Arthritis cases by Disease Type
2.4. 8MM: Historic & Projected Volume of incidence of Psoriatic Arthritis cases by Severity Type
2.5. 8MM: Historic & Projected Volume of Incidence of Psoriatic Arthritis cases by Gender & Age Group
2.6. 8MM: Historic & Projected Volume of Prevalence of Psoriatic Arthritis cases by Disease type
2.7. 8MM: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.8. 8MM: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.9. US: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.10. US: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.11. US: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.12. US: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
2.13. US: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.14. US: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.15. US: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.16. US: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.17. China: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.18. China: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.19. China: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.20. China: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
2.21. China: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.22. China: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.23. China: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.24. China: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.25. Japan: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.26. Japan: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.27. Japan: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.28. Japan: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
2.29. Japan: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.30. Japan: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.31. Japan: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.32. Japan: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.33. Germany: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.34. Germany: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.35. Germany: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.36. Germany: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
2.37. Germany: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.38. Germany: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.39. Germany: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.40. Germany: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.41. UK: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.42. UK: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.43. UK: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.44. UK: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
2.45. UK: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.46. UK: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.47. UK: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.48. UK: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.49. France: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.50. France: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.51. France: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.52. France: Historic & Projected Volume of incidence of Psoriatic Arthritis cases by Severity Type
2.53. France: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.54. France: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.55. France: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.56. France: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.57. Italy: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.58. Italy: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.59. Italy: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.60. Italy: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
2.61. Italy: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.62. Italy: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.63. Italy: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.64. Italy: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.65. Spain: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.66. Spain: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.67. Spain: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.68. Spain: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
2.69. Spain: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.70. Spain: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.71. Spain: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.72. Spain: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group

3. PSORIATIC ARTHRITIS MARKET SIZE & OVERVIEW
3.1. 8MM: Historic & Projected Revenue of Psoriatic Arthritis
3.2. 8MM: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.3. 8MM: Major Approved Drugs in Psoriatic Arthritis
3.4. 8MM: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.5. US: Historic & Projected Revenue of Psoriatic Arthritis
3.6. US: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.7. US: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.8. China: Historic & Projected Revenue of Psoriatic Arthritis
3.9. China: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.10. China: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.11. Japan: Historic & Projected Revenue of Psoriatic Arthritis
3.12. Japan: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.13. Japan: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.14. Germany: Historic & Projected Revenue of Psoriatic Arthritis
3.15. Germany: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.16. Germany: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.17. UK: Historic & Projected Revenue of Psoriatic Arthritis
3.18. UK: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.19. UK: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.20. France: Historic & Projected Revenue of Psoriatic Arthritis
3.21. France: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.22. France: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.23. Italy: Historic & Projected Revenue of Psoriatic Arthritis
3.24. Italy: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.25. Italy: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.26. Spain: Historic & Projected Revenue of Psoriatic Arthritis
3.27. Spain: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.28. Spain: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class

4. PSORIATIC ARTHRITIS MARKETED DRUGS OVERVIEW
4.1. Psoriatic Arthritis Marketed Drugs – An Overview
4.2. Psoriatic Arthritis Marketed Drugs – Summary

5. PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW
5.1. Psoriatic Arthritis Pipeline Drugs – An Overview
5.2. Psoriatic Arthritis Pipeline Drugs – Snapshot
5.3. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot – By Disease type
5.4. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot – By Development Phase
5.5. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot – By Route of Administration
5.6. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot – By Mechanism of Action
5.7. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot – By Molecule type
5.8. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot – By Geography type

6. PSORIATIC ARTHRITIS CLINICAL TRIALS OVERVIEW
6.1. Psoriatic Arthritis Clinical Trials Overview Snapshot
6.2. Psoriatic Arthritis Clinical Trials Overview – By Recruitment Status
6.3. Psoriatic Arthritis Clinical Trials Overview – By Product type
6.4. Psoriatic Arthritis Clinical Trials Overview – By Route of Administration
6.5. Psoriatic Arthritis Clinical Trials Overview – By Molecule type
6.6. Psoriatic Arthritis Clinical Trials Overview – By Geography type

7. PSORIATIC ARTHRITIS MARKET DYNAMICS
7.1. Psoriatic Arthritis Therapeutics Market Drivers
7.2. Psoriatic Arthritis Therapeutics Market Constraints
7.3. Psoriatic Arthritis Therapeutics Market Trends

8. PSORIATIC ARTHRITIS COMPETITIVE LANDSCAPE
8.1. Psoriatic Arthritis Competitive Landscape – Marketed Drugs
8.2. Key Company Profiles
8.3. Other Key Company Profiles
8.4. Competitive Scenario of Psoriatic Arthritis therapeutics market
8.5. Key Company Profile Snapshot
8.6. Other Key Company Profile Snapshot
8.7. Psoriatic Arthritis Competitive Landscape – Pipeline Drugs
8.8. Key Emerging Company Profiles
8.9. Other Key Emerging Company Profiles
8.10. Key Company Profile Snapshot

9. PSORIATIC ARTHRITIS MISCELLANEOUS
9.1. Key Tentative Drug Approvals Timeline
9.2. Key Regulatory Designations
9.3. Key Milestones
9.4. Deals & Collaborations
9.5. Inactive/Discontinued/Dormant Products

10. APPENDIX
10.1. About Arizton
10.2. Research Methodology
10.3. List of Abbreviations

　

ページTOPに戻る


　

Summary

The global psoriatic arthritis treatment market is expected to grow at a CAGR of 8.09% during 2022-2027.

MARKET INSIGHTS

Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation. Psoriatic arthritis occurs in up to 30% of patients with psoriasis, most commonly those aged between 30 and 60 years. It starts about 10 years after psoriasis develops for many people, but some develop PsA first or without ever developing or noticing psoriasis. PsA can occur at any age and affects men and women equally. In recent years, women have contributed more to the global psoriatic arthritis treatment market as they are at greater risk of developing psoriatic arthritis. According to estimates, in the European Union, PsA affects more than 2 million people, and in the United States, about 0.5 million.

The exact cause of PsA is not yet known. Family history plays a strong role; about 40% of those with the disease have a family member with psoriasis or arthritis. Risk factors can include obesity, severe psoriasis, nail disease, and trauma or deep lesions at sites of trauma.

• Psoriatic Arthritis Diagnosis:

There’s no specific test to diagnose psoriatic arthritis. The symptoms are similar to other arthritic diseases such as rheumatoid arthritis, reactive arthritis, and gout. Imaging techniques such as X-rays, CT scans, ultrasound, MRI, and skin biopsies may all be used for diagnosis.

• Psoriatic Arthritis Treatment:

Treatment depends on the extent of pain, swelling, and stiffness. Those with very mild arthritis may require treatment only when their joints are painful and may stop therapy when they feel better. The major types of treatment for psoriatic arthritis are Non-steroidal anti-inflammatory drugs such as ibuprofen (Motrin or Advil) or naproxen (Aleve) as initial treatment. If arthritis does not respond, disease-modifying anti-rheumatic drugs may be prescribed. These include sulfasalazine (Azulfidine), methotrexate (Rheumatrex, Trexall, Otrexup, Rasuvo), cyclosporine (Neoral, Sandimmune, Gengraf), and leflunomide. Sometimes combinations of these drugs may be used together. Azathioprine (Imuran) may help those with severe forms of PSA.

Other treatments include biologics, typically starting with TNF inhibitors such as adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade). Other biologics used for PsA include the IL-17A inhibitors secukinumab (Cosentyx) and ixekizumab (Taltz); IL-12/23 inhibitor ustekinumab (Stelara); IL-23 inhibitors risankizumab-rzaa (Skyrizi) and guselkumab (Tremfya) or other classes abatacept (Orencia). Newer oral medications, such as tofacitinib (Xeljanz), upadacitinib (Rinvoq), and apremilast (Otezla), have also been shown to be effective.

KEY HIGHLIGHTS

The psoriatic arthritis treatment market portfolio contains a total of 25+ assets that are in various phases of development. Most industry-sponsored drugs in active clinical development for psoriatic arthritis are in the Phase III stage. The emerging therapeutics for psoriatic arthritis include Bimekizumab, Tildrakizumab, SHR-0302, Neihulizumab, and many others. Launching these novel emerging drugs will shift the PsA treatment paradigm in the near future. With more than 25 molecules in various stages of development, it is expected that new vendors are likely to enter the industry with a novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating psoriatic arthritis.

• Psoriatic Arthritis: Clinical Trials Scenario

The clinical trial portfolio contains 150+ trials in various development phases. Most industry-sponsored drugs in active clinical development for PsA are in the Phase III stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for psoriatic arthritis have been in the late phase of development, with 58% of trials in Phase II/III & III and only 41% in Phase Phase I-II.

MARKET DRIVERS & TRENDS

• Increasing Adoption of Biological Therapies

Biological therapies such as anti-tumor necrosis factor (TNF) and anti-interleukin antibodies are widely used in the psoriatic arthritis treatment market. With Stelara being biologic approved for PsA in 2013, there is a demand for therapies with novel MOAs that are less immunogenic than current offerings. Many new classes of therapies are looking to enter the psoriatic arthritis treatment market over the next few years. The biologics such as interleukin inhibitors are making inroads into the psoriatic arthritis market owing to better clinical profile and convenient patient dosing.

• Anticipated Launch of Emerging Drugs

A recent wave of biologic products prescribed for psoriatic arthritis treatment will likely create lucrative opportunities. Despite the plethora of therapies currently available to patients with psoriatic arthritis (PsA), there is still room for improvement within the psoriatic arthritis treatment market space.
Arizton anticipates the launch of five new agents among the 8MM, including two interleukins (IL) inhibitors (Bimekizumab; Tildrakizumab) and two oral Janus kinase (JAK) inhibitors (Filgotinib and SHR0302) and one oral tyrosine kinase 2 (TYK2) inhibitor (Deucravacitinib). Launching these late-stage drugs will create an opportunity for growth in the global psoriatic arthritis treatment market.

• Focus on Novel Drugs with Novel Mechanism

Over the past seven years, agents that block inflammatory pathways other than tumor necrosis factor (TNF) represent new options for treating psoriasis arthritis (PsA). The therapeutic agents targeting the IL-23/IL-17 axis have been proven to be very effective in psoriatic arthritis, some are already in the therapeutic armamentarium, and others are in development. IL-23/IL-17 axis cytokines are essential players in the pathogenesis of psoriasis and PsA. Inhibition of IL-23 and IL-17 with monoclonal antibodies is a very effective therapy in the psoriatic arthritis treatment market. Over the next five years, Arizton expects to see a surge of innovation emerging from the research and development pipeline and a range of technology-enabled transformations that will expand the evidence-basis for interventions and bring measurable improvements to outcomes.

SEGMENTATION ANALYSIS

• Drug Class: TNF-Alpha inhibitors account for a significant share of the global psoriatic arthritis treatment market. However, interleukin inhibitors are expected to be the fastest growing segment during the forecast period. Recently approved interleukin inhibitors such as Skyrizi (risankizumab-rzaa) and Cosentyx (Secukinumab) are expected to drive the global psoriatic arthritis treatment market during the forecast period.

Segmentation by Drug Class
• TNF Inhibitors
• Interleukin Inhibitors
• NSAIDs
• Other classes of Drugs

• Gender Type: Women accounted for a significant share of the global psoriatic arthritis treatment market under the gender type segment. This is because women have been at greater risk of psoriatic arthritis in recent years.

Segmentation by Gender Type
• Men
• Women

• Disease Type: Enthesitis is expected to account for a significant share. However, Dactylitis is expected to be the fastest growing segment during the forecast period.

Segmentation by Disease Type
• Spondylitis
• Enthesitis
• Dactylitis

• Age Group: People aged 50 years and below are expected to account for a significant share of the global psoriatic arthritis treatment market.

Segmentation by Age Group
• 50 years and Below
• 50 years and Above

• Severity Type: People with mild form are expected to account for a significant share of the global psoriatic arthritis treatment market under the severity type category. However, people with moderate form are expected to be the fastest growing segment during the forecast period.

Segmentation by Severity Type
• Moderate
• Mild
• Severe

GEOGRAPHICAL OUTLOOK

The U.S. dominates the global psoriatic arthritis treatment market by geography due to the healthcare affordability in the U.S., the knowledge and awareness amongst the people, and the technological advancement in this region. However, Germany is expected to grow faster with a high CAGR in the PsA drug industry due to the rise in access and quality of healthcare, increased awareness about disease management, and rising healthcare expenditure in this region. The trend of biosimilars in emerging markets, such as China and Japan, could potentially alter this region's psoriatic arthritis therapeutic landscape.

According to Arizton estimates, the prevalent cases of psoriatic arthritis were high in China, followed by Spain and the U.K. in 2020. The increasing prevalence of psoriatic arthritis is driving the growth of the psoriatic arthritis treatment market. According to estimates, more than two million people in European Union were affected by PsA in 2014.

Segmentation by Geography

• North America
o United States
• APAC
o China
o Japan
• Europe
o U.K.
o France
o German
o Italy
o Spain

COMPETITIVE LANDSCAPE

The global psoriatic arthritis treatment market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating PsA. The U.S. Food and Drug Administration (FDA) approved the interleukin antibody Stelara (Ustekinumab) for treating psoriatic arthritis in 2013. Recently the FDA approved interleukins such as Skyrizi (risankizumab-rzaa) in 2022 and Cosentyx (secukinumab) in 2021 for treating PsA. Although generic products continue to capture significant psoriatic arthritis treatment market share, the arrival of biologics and other targeted therapies indicate a paradigm shift in this therapeutic space through the forecast period.

Companies such as AbbVie Inc., Johnson & Johnson, Takeda Pharmaceutical Co Ltd, Biogen Inc, UCB SA, Amgen, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, and Novartis are the major players in the global psoriatic arthritis treatment market. These players are focused on adopting growth strategies to strengthen their product portfolio. These companies have adopted strategies such as collaborations & acquisitions, expansion of geographical footprint, investments in research & development, and manufacture of novel drugs to compete in the global psoriatic arthritis treatment market.

The other prominent players operating in the psoriatic arthritis treatment market include Sun Pharmaceuticals, Bausch Health Companies Inc, Jiangsu HengRui Medicine Co. Ltd, Biocad Biopharmaceutical, Meiji Holdings Co Ltd, and Bio-Thera. These players are focused on R&D initiatives for developing technologically advanced and innovative psoriatic drugs and are also entering collaborations to maintain their position in the industry.

Key Vendors
• AbbVie Inc.
• Johnson & Johnson
• UCB SA
• Amgen
• Bristol-Myers Squibb
• Pfizer
• Eli Lilly and Company
• Novartis

Other Prominent Vendors
• Samsung Bioepis
• Boehringer Ingelheim
• Mylan
• Merck & Co., Inc
• Coherus BioSciences, Inc

Key Emerging Vendors with Late Stage Pipeline Drugs
• Sun Pharmaceuticals
• Bausch Health Companies Inc
• Jiangsu HengRui Medicine Co. Ltd
• Biocad Biopharmaceutical
• Meiji Holdings Co Ltd
• Bio-Thera

REPORT COVERS

• Detailed overview of psoriatic arthritis treatment market, including disease definition, classification, diagnosis, and treatment pattern.
• Overview of the global trends of the psoriatic arthritis treatment market in the eight major markets (8MM)
• Historical, current, and projected patient pool of PsA in the eight major markets (8MM) for the 2018 – 2027 period
• In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
• Psoriatic arthritis treatment market share of the market players, company profiles, product specifications, and competitive landscape
• Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
• Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities.
• Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for PsA across the complete product development cycle, including all clinical and non-clinical stages
• Detailed overview of clinical trial activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and geography type for psoriatic arthritis across all clinical stages
• Coverage of dormant and discontinued pipeline projects along with the reasons across PsA
• Coverage of significant milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the psoriatic arthritis treatment market.

KEY QUESTIONS ANSWERED
1. How big is the global psoriatic arthritis treatment market?
2. What is the growth rate of the global psoriatic arthritis treatment market?
3. What factors drive the growth of the psoriatic arthritis treatment market?
4. Who are the leading vendors operating in the psoriatic arthritis treatment market?
5. Which region holds the largest share in the global psoriatic arthritis treatment market?



ページTOPに戻る


Table of Contents

1. PSORIATIC ARTHRITIS OVERVIEW
1.1. Psoriatic Arthritis Disease – An Overview

2. PSORIATIC ARTHRITIS EPIDEMIOLOGY & OVERVIEW
2.1. 8MM: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.2. 8MM: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.3. 8MM: Historic & Projected Volume of incidence of Psoriatic Arthritis cases by Disease Type
2.4. 8MM: Historic & Projected Volume of incidence of Psoriatic Arthritis cases by Severity Type
2.5. 8MM: Historic & Projected Volume of Incidence of Psoriatic Arthritis cases by Gender & Age Group
2.6. 8MM: Historic & Projected Volume of Prevalence of Psoriatic Arthritis cases by Disease type
2.7. 8MM: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.8. 8MM: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.9. US: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.10. US: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.11. US: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.12. US: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
2.13. US: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.14. US: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.15. US: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.16. US: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.17. China: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.18. China: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.19. China: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.20. China: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
2.21. China: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.22. China: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.23. China: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.24. China: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.25. Japan: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.26. Japan: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.27. Japan: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.28. Japan: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
2.29. Japan: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.30. Japan: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.31. Japan: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.32. Japan: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.33. Germany: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.34. Germany: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.35. Germany: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.36. Germany: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
2.37. Germany: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.38. Germany: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.39. Germany: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.40. Germany: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.41. UK: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.42. UK: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.43. UK: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.44. UK: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
2.45. UK: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.46. UK: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.47. UK: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.48. UK: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.49. France: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.50. France: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.51. France: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.52. France: Historic & Projected Volume of incidence of Psoriatic Arthritis cases by Severity Type
2.53. France: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.54. France: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.55. France: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.56. France: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.57. Italy: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.58. Italy: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.59. Italy: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.60. Italy: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
2.61. Italy: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.62. Italy: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.63. Italy: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.64. Italy: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group
2.65. Spain: Historic & Projected Volume of Incidence & Prevalence of Psoriatic Arthritis
2.66. Spain: Comparative Analysis of Incidence & Prevalence of Psoriatic Arthritis
2.67. Spain: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Disease Type
2.68. Spain: Historic & Projected Volume of incidence of Psoriatic Arthritis Cases by Severity Type
2.69. Spain: Historic & Projected Volume of Incidence of Psoriatic Arthritis Cases by Gender & Age Group
2.70. Spain: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Disease Type
2.71. Spain: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Severity Type
2.72. Spain: Historic & Projected Volume of Prevalence of Psoriatic Arthritis Cases by Gender & Age Group

3. PSORIATIC ARTHRITIS MARKET SIZE & OVERVIEW
3.1. 8MM: Historic & Projected Revenue of Psoriatic Arthritis
3.2. 8MM: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.3. 8MM: Major Approved Drugs in Psoriatic Arthritis
3.4. 8MM: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.5. US: Historic & Projected Revenue of Psoriatic Arthritis
3.6. US: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.7. US: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.8. China: Historic & Projected Revenue of Psoriatic Arthritis
3.9. China: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.10. China: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.11. Japan: Historic & Projected Revenue of Psoriatic Arthritis
3.12. Japan: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.13. Japan: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.14. Germany: Historic & Projected Revenue of Psoriatic Arthritis
3.15. Germany: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.16. Germany: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.17. UK: Historic & Projected Revenue of Psoriatic Arthritis
3.18. UK: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.19. UK: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.20. France: Historic & Projected Revenue of Psoriatic Arthritis
3.21. France: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.22. France: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.23. Italy: Historic & Projected Revenue of Psoriatic Arthritis
3.24. Italy: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.25. Italy: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class
3.26. Spain: Historic & Projected Revenue of Psoriatic Arthritis
3.27. Spain: Historic & Projected Revenue of Psoriatic Arthritis Snapshot
3.28. Spain: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity, Age Group & Drug Class

4. PSORIATIC ARTHRITIS MARKETED DRUGS OVERVIEW
4.1. Psoriatic Arthritis Marketed Drugs – An Overview
4.2. Psoriatic Arthritis Marketed Drugs – Summary

5. PSORIATIC ARTHRITIS PIPELINE DRUGS OVERVIEW
5.1. Psoriatic Arthritis Pipeline Drugs – An Overview
5.2. Psoriatic Arthritis Pipeline Drugs – Snapshot
5.3. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot – By Disease type
5.4. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot – By Development Phase
5.5. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot – By Route of Administration
5.6. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot – By Mechanism of Action
5.7. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot – By Molecule type
5.8. Psoriatic Arthritis Pipeline Drugs Overview & Snapshot – By Geography type

6. PSORIATIC ARTHRITIS CLINICAL TRIALS OVERVIEW
6.1. Psoriatic Arthritis Clinical Trials Overview Snapshot
6.2. Psoriatic Arthritis Clinical Trials Overview – By Recruitment Status
6.3. Psoriatic Arthritis Clinical Trials Overview – By Product type
6.4. Psoriatic Arthritis Clinical Trials Overview – By Route of Administration
6.5. Psoriatic Arthritis Clinical Trials Overview – By Molecule type
6.6. Psoriatic Arthritis Clinical Trials Overview – By Geography type

7. PSORIATIC ARTHRITIS MARKET DYNAMICS
7.1. Psoriatic Arthritis Therapeutics Market Drivers
7.2. Psoriatic Arthritis Therapeutics Market Constraints
7.3. Psoriatic Arthritis Therapeutics Market Trends

8. PSORIATIC ARTHRITIS COMPETITIVE LANDSCAPE
8.1. Psoriatic Arthritis Competitive Landscape – Marketed Drugs
8.2. Key Company Profiles
8.3. Other Key Company Profiles
8.4. Competitive Scenario of Psoriatic Arthritis therapeutics market
8.5. Key Company Profile Snapshot
8.6. Other Key Company Profile Snapshot
8.7. Psoriatic Arthritis Competitive Landscape – Pipeline Drugs
8.8. Key Emerging Company Profiles
8.9. Other Key Emerging Company Profiles
8.10. Key Company Profile Snapshot

9. PSORIATIC ARTHRITIS MISCELLANEOUS
9.1. Key Tentative Drug Approvals Timeline
9.2. Key Regulatory Designations
9.3. Key Milestones
9.4. Deals & Collaborations
9.5. Inactive/Discontinued/Dormant Products

10. APPENDIX
10.1. About Arizton
10.2. Research Methodology
10.3. List of Abbreviations

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

Arizton Advisory & Intelligence 社の最新刊レポート

本レポートと同じKEY WORD（pipeline）の最新刊レポート


よくあるご質問


Arizton Advisory & Intelligence社はどのような調査会社ですか?


Arizton Advisory & Intelligenceは世界の広範な市場を調査しています。   主な調査カテゴリ   ◇ 消費財＆小売　　◇ 自動車＆モビリティ　　◇ スマートテクノロ... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/07/05　10:26

162.17 円

175.82 円

209.73 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.